Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

Abstract Background Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efficacy of ibrutinib combined with companion drugs for advance...

Full description

Bibliographic Details
Main Authors: Do-Youn Oh, Maria Alsina Maqueda, David I. Quinn, Peter J. O’Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K. Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P. Dean, Hendrik-Tobias Arkenau
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Cancer
Subjects:
Renal cell carcinoma
Gastric adenocarcinoma
Colorectal carcinoma
Ibrutinib
Everolimus
Docetaxel
Online Access:https://doi.org/10.1186/s12885-023-11539-1

Internet

https://doi.org/10.1186/s12885-023-11539-1

Similar Items